ERBB2 and breast carcinoma: Regardless of sex, a study assessing the risk of cardiotoxicity linked to associated trastuzumab emtansine (TDM1) and radiotherapy in individuals with early-stage HER2-positive breast cancer observed no apparent change in global longitudinal strain (GLS) or LVEF following radiation [298].